NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to ...

AbbVie’s blockbuster arthritis medication, adalimumab (Humira), now has an FDA-approved competitor: Amgen’s adalimumab-atto, also called Amjevita. AbbVie’s blockbuster arthritis medication, adalimumab ...

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...

More than five million people worldwide have RA, and most of them are considered to be in the prime of their working lives (between 30-50 years of age). The data are from DE032, an economic companion ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In 2021, Humira — the blockbuster biologic that has for ...

EXTON, PA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...

Results from ATLAS, a Long-Term, Open-Label Extension Study Presented at ACR, Highlight Impact of HUMIRA on Signs and Symptoms and Other Disease Measures in Patients with Active AS ABBOTT PARK, Ill., ...

Yuflyma is Celltrion USA's high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar JERSEY CITY, N.J.--(BUSINESS WIRE)--Celltrion USA today announced the launch of ...